Effects of thiazolidinediones on differentiation, proliferation, and apoptosis
- PMID: 17579114
- DOI: 10.1158/1541-7786.MCR-06-0278
Effects of thiazolidinediones on differentiation, proliferation, and apoptosis
Abstract
Thiazolidinediones induce adipocyte differentiation and thereby limit proliferative potential; hence, early investigations focused on their ability to modulate cellular proliferation and apoptosis. Several lines of evidence indicate significant thiazolidinedione-mediated antitumor activity. An emerging view is that some antitumor effects are totally or partially peroxisome proliferator-activated receptor-gamma (PPARgamma) dependent, whereas others are PPARgamma independent. The aim of this review is to examine the current evidence about the molecular mechanisms by which thiazolidinediones augment cellular differentiation, inhibit cellular proliferation, and induce apoptosis. We first address the role of thiazolidinediones and/or PPARgamma on Wnt/beta-catenin signaling pathway as it affects cellular differentiation and then discuss other pathways that are also involved in differentiation as well as proliferation and apoptosis.
Similar articles
-
PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.Int J Biochem Cell Biol. 2009 Apr;41(4):844-52. doi: 10.1016/j.biocel.2008.08.037. Epub 2008 Sep 6. Int J Biochem Cell Biol. 2009. PMID: 18822385
-
Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.Endocr Relat Cancer. 2006 Jun;13(2):401-13. doi: 10.1677/erc.1.01182. Endocr Relat Cancer. 2006. PMID: 16728570 Review.
-
Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.Endocr Relat Cancer. 2005 Jun;12(2):291-303. doi: 10.1677/erc.1.00973. Endocr Relat Cancer. 2005. PMID: 15947104
-
Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.Cell Biol Int. 2008 Aug;32(8):906-12. doi: 10.1016/j.cellbi.2008.04.011. Epub 2008 Apr 10. Cell Biol Int. 2008. PMID: 18474441
-
Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.Urol Oncol. 2009 Nov-Dec;27(6):585-91. doi: 10.1016/j.urolonc.2008.11.002. Epub 2009 Jan 22. Urol Oncol. 2009. PMID: 19162510 Review.
Cited by
-
Pancreatic β Cell Mass Death.Front Pharmacol. 2016 Apr 6;7:83. doi: 10.3389/fphar.2016.00083. eCollection 2016. Front Pharmacol. 2016. PMID: 27092078 Free PMC article. Review.
-
DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling.Invest New Drugs. 2010 Dec;28(6):783-90. doi: 10.1007/s10637-009-9313-x. Epub 2009 Sep 16. Invest New Drugs. 2010. PMID: 19756375
-
Cytotoxic effects of statins and thiazolidinediones on meningioma cells.J Neurooncol. 2011 May;102(3):383-93. doi: 10.1007/s11060-010-0351-1. Epub 2010 Aug 30. J Neurooncol. 2011. PMID: 20803306
-
Mechanisms Governing Metabolic Heterogeneity in Breast Cancer and Other Tumors.Front Oncol. 2021 Sep 23;11:700629. doi: 10.3389/fonc.2021.700629. eCollection 2021. Front Oncol. 2021. PMID: 34631530 Free PMC article. Review.
-
Impact of elastin-derived VGVAPG peptide on bidirectional interaction between peroxisome proliferator-activated receptor gamma (Pparγ) and beta-galactosidase (β-Gal) expression in mouse cortical astrocytes in vitro.Naunyn Schmiedebergs Arch Pharmacol. 2019 Apr;392(4):405-413. doi: 10.1007/s00210-018-1591-4. Epub 2018 Dec 3. Naunyn Schmiedebergs Arch Pharmacol. 2019. PMID: 30511276
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources